FDMT4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal. | ||
 4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates 4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 0.00% and +142.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates MediWound (MDWD) delivered earnings and revenue surprises of -1.32% and +19.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +14.29% and +1.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Bioventus (BVS) Q2 Earnings Meet Estimates Bioventus (BVS) delivered earnings and revenue surprises of 0.00% and -1.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls | TThe Fly | |
 Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates Amneal (AMRX) delivered earnings and revenue surprises of +25.00% and +3.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||